MENU
+Compare
CRIS
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$3.22
Change
-$0.23 (-6.67%)
Capitalization
27.26M

CRIS Curis Forecast, Technical & Fundamental Analysis

a drug company

Industry Biotechnology
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for CRIS with price predictions
Dec 17, 2024

CRIS sees MACD Histogram crosses below signal line

CRIS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 12, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 32 instances where the indicator turned negative. In of the 32 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRIS entered a downward trend on November 26, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRIS's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.099) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). CRIS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (1.830) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a drug company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
128 Spring Street
Phone
+1 617 503-6500
Employees
49
Web
https://www.curis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCTX0.650.04
+6.17%
BriaCell Therapeutics Corp
CCEP77.550.12
+0.15%
Coca-Cola Europacific Partners plc
BRZE44.75-0.03
-0.07%
Braze
FSM4.60-0.04
-0.86%
Fortuna Mining Corp
BMRC24.60-0.23
-0.93%
Bank of Marin Bancorp

CRIS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with ORMP. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRIS
1D Price
Change %
CRIS100%
-0.86%
ORMP - CRIS
34%
Loosely correlated
-1.67%
GOSS - CRIS
31%
Poorly correlated
+1.71%
ALNY - CRIS
31%
Poorly correlated
+1.06%
AMRN - CRIS
30%
Poorly correlated
-0.80%
AXON - CRIS
30%
Poorly correlated
-2.09%
More